Skip to main content
. Author manuscript; available in PMC: 2011 Mar 27.
Published in final edited form as: Transplantation. 2010 Mar 27;89(6):667–676. doi: 10.1097/TP.0b013e3181ca9048

Figure 3. HEL-CTL induce B cell tolerance in vivo.

Figure 3

HEL-CTL or control vector-transduced CTL (107) were adoptively transferred i.v. into C57BL/6 mice 9, 6, and 3 days prior to immunization with HEL/CFA. Serum was isolated prior to initial immunization with HEL (day 0) and on day 28 and antibody titers tested by staining T cells transduced with the HEL construct or with control vector with serum from the treated animals. (A) Serum collected from mice on day 0 prior to immunization. Plot shows mean fluorescence intensity (MFI) of staining against HEL-transduced cells at various dilutions or control MSCV vector-transduced cells at the highest titer only. (B) Serum collected from mice on day 28 after immunization. (C) Serum collected on day 0 from mice that also received 50 μg LPS i.p. with each infusion of the HEL- or vector-modified CTL. (D) Serum collected on day 28 from mice treated as in (C). Mean ± S.E.M. is shown for each value. 6-8 mice were studied per treatment group in this representative experiment.